Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Treatment Protocol For Patients With Gastrointestinal Stromal Tumor Who Are Ineligible For Participation In Other SU011248 Protocols And Are Refractory To Or Intolerant Of Imatinib Mesylate

NCT00094029 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00094029
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00094029 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Treatment Protocol For Patients With Gastrointestinal Stromal Tumor Who Are Ineligible For Participation In Other SU011248 Protocols And Are Refractory To Or Intolerant Of Imatinib Mesylate
Lead sponsor
Pfizer
Phase
Expanded access
Overall status
Approved for marketing
Start date
September 30, 2004
Completion date
October 31, 2011
Enrollment
Not reported
Sites
118

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal neoplasm